Table 4.
Clinical and therapeutic characteristics of fingolimod-switching patients
| Post-fingolimod treatmenta | N (%) | F (%) | Age, years (mean ± SD)c | WA of fingolimod, monthsd | EDSS (median score) | Annualized relapse rate | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nc | Prec | Ne | Poste | Prec | WA | Postf | |||||
| Totalb | 901 (100.0) | 75.4 | 40.0 ± 10.6 | 2.0 (1.0, 5.0) | 458 | 3.0 | 429 | 3.0 | 0.37 | 0.47 | 0.19 |
| Ocrelizumab | 178 (19.8) | 71.9 | 41.8 ± 10.3 | 3.0 (1.0, 5.0) | 136 | 3.5 | 101 | 3.0 | 0.32 | 0.41 | 0.15 |
| Natalizumab | 171 (19.0) | 80.7 | 36.6 ± 10.0 | 2.0 (1.0, 4.0) | 79 | 2.5 | 74 | 2.5 | 0.39 | 0.66 | 0.17 |
| Dimethyl fumarate | 99 (11.0) | 69.7 | 40.4 ± 9.5 | 2.0 (1.0, 6.0) | 31 | 2.5 | 43 | 3.0 | 0.21 | 0.65 | 0.15 |
| Alemtuzumab | 95 (10.5) | 75.8 | 35.5 ± 9.7 | 3.0 (2.0, 4.5) | 33 | 3.0 | 45 | 3.0 | 0.63 | 0.53 | 0.15 |
| Fingolimod after break | 85 (9.4) | 72.9 | 40.3 ± 11.0 | n.a | 39 | 2.0 | 40 | 3.0 | 0.37 | n.a | 0.26 |
| Glatiramer acetate | 67 (7.4) | 79.1 | 42.9 ± 11.5 | 1.0 (0.0, 2.0) | 24 | 2.5 | 29 | 2.5 | 0.41 | 0.16 | 0.27 |
| Cladribine | 46 (5.1) | 78.3 | 39.9 ± 10.4 | 3.0 (2.0, 5.0) | 33 | 2.5 | 24 | 2.25 | 0.40 | 0.47 | 0.09 |
| Daclizumab | 35 (3.9) | 71.4 | 40.4 ± 11.7 | 2.0 (1.0, 2.5) | 19 | 3.0 | 26 | 3.0 | 0.52 | 0.00 | 0.34 |
| Interferon beta | 33 (3.7) | 78.8 | 39.4 ± 11.7 | 1.0 (0.0, 7.0) | 8 | 2.25 | 8 | 2.5 | 0.36 | 0.00 | 0.44 |
| Teriflunomide | 33 (3.7) | 87.9 | 45.3 ± 9.2 | 3.0 (2.0, 4.0) | 15 | 3.0 | 15 | 3.0 | 0.51 | 0.27 | 0.18 |
| Study medication | 15 (1.7) | 46.7 | 51.3 ± 9.2 | 1.0 (0.0, 6.0) | 15 | 4.0 | 5 | 5.0 | 0.00 | 0.69 | 0.28 |
| GCS | 11 (1.2) | 72.7 | 45.1 ± 9.5 | n.a | 8 | 4.75 | 4 | 6.25 | 0.11 | 0.35 | 0.00 |
| Rituximab | 11 (1.2) | 72.7 | 41.4 ± 10.2 | 2.0 (2.0, 3.0) | 9 | 3.0 | 15 | 3.0 | 0.44 | 0.50 | 0.22 |
F proportion of female patients, GCS regular glucocorticosteroid pulse therapy, N (%) number of patients (proportion of patients), WA washout period
aGroups with statistically sufficient numbers of patients (N ≥ 10) are shown in detail
bWe excluded 43 of the fingolimod-switching PwMS (N = 944) from this analysis due to missing data on switch dates
cAt last visit/during the last year under fingolimod treatment
dMedian (25% quartile, 75% quartile)
e6–12 months after the initiation of the post-fingolimod treatment
fFrom the start of the post-fingolimod treatment until the end of the observation period